Persistent Systemic Inflammation is Associated with Poor Clinical Outcomes in COPD: A Novel Phenotype
暂无分享,去创建一个
Courtney Crim | Edwin K. Silverman | David A. Lomas | Stephen I. Rennard | Bartolome Celli | Bruce E. Miller | Ruth Tal-Singer | Harvey O. Coxson | Per Bakke | L. Edwards | E. Silverman | B. Celli | J. Vestbo | P. Bakke | D. Lomas | B. Miller | A. Agustí | E. Wouters | H. Coxson | W. MacNee | J. Yates | S. Rennard | R. Tal-Singer | R. Mayer | P. Calverley | C. Crim | Jørgen Vestbo | Alvar Agustí | William MacNee | Emiel Wouters | Lisa D. Edwards | Julie C. Yates | Ruth J. Mayer | Peter M. A. Calverley | W. Macnee
[1] P. Bakke,et al. Systemic inflammatory markers in COPD: results from the Bergen COPD Cohort Study , 2009, European Respiratory Journal.
[2] J. Vestbo,et al. Current controversies and future perspectives in chronic obstructive pulmonary disease. , 2011, American journal of respiratory and critical care medicine.
[3] Johan Gabrielsson,et al. Non-compartmental analysis. , 2012, Methods in molecular biology.
[4] C. Franceschi,et al. Inflammation markers predicting frailty and mortality in the elderly. , 2006, Experimental and molecular pathology.
[5] E. Benjamin,et al. Systemic inflammation and COPD: the Framingham Heart Study. , 2008, Chest.
[6] Edwin K Silverman,et al. Chronic obstructive pulmonary disease phenotypes: the future of COPD. , 2010, American journal of respiratory and critical care medicine.
[7] N. Anthonisen,et al. Circulating fibronectin to C-reactive protein ratio and mortality: a biomarker in COPD? , 2008, European Respiratory Journal.
[8] Ciro Casanova,et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. , 2004, The New England journal of medicine.
[9] Josep Roca,et al. Identification and prospective validation of clinically relevant chronic obstructive pulmonary disease (COPD) subtypes , 2010, Thorax.
[10] B. Nordestgaard,et al. Elevated plasma fibrinogen associated with reduced pulmonary function and increased risk of chronic obstructive pulmonary disease. , 2001, American journal of respiratory and critical care medicine.
[11] K. Rabe,et al. From COPD to chronic systemic inflammatory syndrome? , 2007, The Lancet.
[12] J. Soriano,et al. Outcomes in patients with chronic obstructive pulmonary disease and obstructive sleep apnea: the overlap syndrome. , 2010, American journal of respiratory and critical care medicine.
[13] Sanjay Sethi,et al. New paradigms in the pathogenesis of chronic obstructive pulmonary disease II. , 2009, Proceedings of the American Thoracic Society.
[14] A. Schols,et al. Systemic effects in COPD. , 2002, Chest.
[15] Alan D. Lopez. THE GLOBAL BURDEN OF DISEASE 1990-2020 , 2001 .
[16] A. Buist. Standardization of spirometry. , 1987, The American review of respiratory disease.
[17] Carl Nathan,et al. Points of control in inflammation , 2002, Nature.
[18] J. Wedzicha,et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. , 2010, The New England journal of medicine.
[19] D. Sin,et al. The effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease. , 2008, American journal of respiratory and critical care medicine.
[20] C. Block,et al. Mechanisms linking obesity with cardiovascular disease , 2006, Nature.
[21] B. Nordestgaard,et al. C reactive protein and chronic obstructive pulmonary disease: a Mendelian randomisation approach , 2010, Thorax.
[22] F. Martinez,et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. , 2007, American journal of respiratory and critical care medicine.
[23] R. Vasan,et al. Biomarkers of Cardiovascular Disease: Molecular Basis and Practical Considerations , 2006, Circulation.
[24] B. Celli,et al. Addressing the complexity of chronic obstructive pulmonary disease: from phenotypes and biomarkers to scale-free networks, systems biology, and P4 medicine. , 2011, American journal of respiratory and critical care medicine.
[25] X. Busquets,et al. Systemic effects of chronic obstructive pulmonary disease , 2003, European Respiratory Journal.
[26] Lisa Rosenbaum,et al. Facing a "slow-motion disaster"--the UN meeting on noncommunicable diseases. , 2011, The New England journal of medicine.
[27] Charles Auffray,et al. An integrative systems biology approach to understanding pulmonary diseases. , 2010, Chest.
[28] D. Mannino,et al. Global burden of COPD: risk factors, prevalence, and future trends , 2007, The Lancet.
[29] John L. Hankinson,et al. Standardization of Spirometry, 1994 Update. American Thoracic Society. , 1995, American journal of respiratory and critical care medicine.
[30] J E Cotes,et al. Lung volumes and forced ventilatory flows , 1993, European Respiratory Journal.
[31] W. MacNee,et al. Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE) , 2008, European Respiratory Journal.
[32] C. Franceschi,et al. Inflamm‐ageing and lifelong antigenic load as major determinants of ageing rate and longevity , 2005, FEBS letters.
[33] J. Soriano,et al. Systemic inflammation in chronic obstructive pulmonary disease: a population-based study , 2010, Respiratory research.
[34] S. Bangert,et al. Clinical Biochemistry: Metabolic and Clinical Aspects , 2008 .
[35] J E Cotes,et al. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. , 1993, The European respiratory journal. Supplement.
[36] B. Celli,et al. Use of proteomic patterns of serum biomarkers in patients with chronic obstructive pulmonary disease: correlation with clinical parameters. , 2006, Proceedings of the American Thoracic Society.
[37] S. Bojesen,et al. C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. , 2007, American journal of respiratory and critical care medicine.
[38] W. Cullen,et al. Research confuses me: what is the difference between case-control and cohort studies in quantitative research? , 2013, Irish medical journal.
[39] ATS statement: guidelines for the six-minute walk test. , 2002, American journal of respiratory and critical care medicine.
[40] Yasutaka Nakano,et al. Airway wall thickening and emphysema show independent familial aggregation in chronic obstructive pulmonary disease. , 2008, American journal of respiratory and critical care medicine.
[41] L. Kantor,et al. NIH Roadmap for Medical Research , 2008, Alcohol research & health : the journal of the National Institute on Alcohol Abuse and Alcoholism.
[42] Dave Singh,et al. The repeatability of interleukin-6, tumor necrosis factor-α, and C-reactive protein in COPD patients over one year , 2009, International journal of chronic obstructive pulmonary disease.
[43] D. Mannino,et al. International variation in the prevalence of COPD (The BOLD Study): a population-based prevalence study , 2007, The Lancet.
[44] J. Barendregt,et al. Global burden of disease , 1997, The Lancet.
[45] A. Barabasi,et al. Network medicine : a network-based approach to human disease , 2010 .
[46] John D. Storey,et al. A network-based analysis of systemic inflammation in humans , 2005, Nature.
[47] L. Hood,et al. Systems medicine and integrated care to combat chronic noncommunicable diseases , 2011, Genome Medicine.
[48] Buist As. Standardization of spirometry. , 1987 .
[49] A. Agustí. Systemic effects of chronic obstructive pulmonary disease: what we know and what we don't know (but should). , 2007, Proceedings of the American Thoracic Society.
[50] Edwin K Silverman,et al. Characterisation of COPD heterogeneity in the ECLIPSE cohort , 2010, Respiratory research.
[51] A Senthilselvan,et al. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis , 2004, Thorax.